Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 2186 · · 10 pages · English
Summary by 6ix AI
It confirms that the total authorized share capital remains unchanged at a specified amount. The report also states that there were no changes in the number of issued shares or treasury shares during the month. Additionally, it confirms compliance with public float requirements as of the end of the month.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Luye Pharma
- Interim Report 2026
- Luye Pharma Announces 2026 Interim Results
- Luye Pharma Announces Successful Completion of a U.S. Bridging Clinical Trial of Its Innovative Drug LY03015 (VMAT2 Inhibitor/Sigma-1R...
- Luye Pharma Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China
- Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015
Follow Luye Pharma into a list and get an email when it puts out news.
Follow Luye Pharma